RecruitingNot ApplicableNCT07089381

Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.

Sponsor

Ain Shams University

Enrollment

118 participants

Start Date

Aug 1, 2025

Study Type

INTERVENTIONAL

Conditions

Rheumatic Arthritis Inflamation Rheumatoid Arthritis (RA) Prevention Antioxidant Anti Oxidative Stress Anti Aging

Summary

The aim of the current study is to evaluate the effects of resveratrol on the clinical outcome(s) of patients with moderate rheumatoid arthritis. Objectives : 1. To investigate the effects of Resveratrol on inflammation and oxidative stress by measuring: * Serum Sirtuin 1(SIRT1) * Serum Myeloperoxidase (MPO) * Serum C-reactive protein (CRP) 2. To investigate the effects of Resveratrol on disease activity by measuring the disease activity (DAS28 score). 3. To investigate the effect of Resveratrol on improving the quality of life using the Health Assessment Questionnaire Disability index (HAQ-DI). 4. To assess any adverse effects related to Resveratrol. Patients: Eligible patients (no=118) will be randomly assigned in a 1:1 ratio to one of two groups: 1. Control group: 59 patients will receive the standard treatment for management of RA for 3 months. 2. Resveratrol group: 59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix Egypt) (given as one 1000 mg tablets once daily) for 3 months.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether resveratrol — a natural compound found in red wine and grapes — can reduce inflammation and improve symptoms in people with rheumatoid arthritis (RA), a chronic condition where the immune system attacks the joints. **You may be eligible if...** - You are over 18 years old - You have a confirmed diagnosis of rheumatoid arthritis according to established criteria - You have moderate to high disease activity despite current treatment - Your medications have been stable for at least 3 months **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have significant kidney or liver disease - You have allergies to resveratrol or its ingredients - You have recently started or changed RA medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTResveratrol 1 gm.

59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix, Egypt) (given as one 1000 mg tablets once daily) for 3 months.

DRUGMethotrexate

59 patients will receive the standard treatment for management of RA for 3 months